Antisense-based cancer therapeutics: are we there yet?
Despite significant advances that have been made in recent years, there is still an urgent need for novel, more effective and less toxic therapeutics for human cancer. Among many new molecular therapeutics being explored for cancer therapy, antisense oligonucleotides are a promising nucleic acid-based approach, with numerous antisense agents being evaluated in preclinical studies and several anticancer antisense drugs in clinical trials. Although there are still a few problems facing the development of antisense strategies for cancer therapy, with progress made in chemical modifications, target selection and drug delivery systems, antisense oligonucleotides are emerging as a novel approach to cancer therapy used alone or in combination with conventional treatments such as chemotherapy and radiation therapy.
Rayburn
Elizabeth Rose
ER
University of Alabama at Birmingham, Department of Pharmacology and Toxicology, Division of Clinical Pharmacology, VH 113, 1670 University Blvd., Birmingham, AL 35294, USA
Wang
Hui
H
Zhang
Ruiwen
R
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000737:chemistry; D016503:Drug Delivery Systems / Q000379:methods*; D015507:Drugs, Investigational / Q000008:administration & dosage / Q000737:chemistry; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D016376:Oligonucleotides, Antisense / Q000008:administration & dosage* / Q000737:chemistry
D000970:Antineoplastic Agents; D015507:Drugs, Investigational; D016376:Oligonucleotides, Antisense